Combined Use of Cabozantinib and Nivolumab in Clinical Practice
Open Access
- 18 April 2024
- journal article
- research article
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 14 (1) , 94-100
Abstract
Комбинированное применение кабозантиниба и ниволумаба в клинической практикеKeywords
This publication has 28 references indexed in Scilit:
- Clear cell renal cell carcinoma ontogeny and mechanisms of lethalityNature Reviews Nephrology, 2020
- The Immunotherapy Landscape in Renal Cell CarcinomaBioDrugs, 2020
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunityExperimental & Molecular Medicine, 2020
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trialAnnals of Oncology, 2020
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookCancer Treatment Reviews, 2020
- Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials DataTargeted Oncology, 2019
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 2018
- Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 RegistryClinical Genitourinary Cancer, 2017
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013